We are in a transformative era for the pharmaceutical industry, with steady growth of revolutionary large molecule products aimed at addressing previously unmet medical needs. We must adopt new strategies and business models to help drive these discoveries from concept to reality. Drug manufacturers need sustainable partnerships throughout the product life cycle, rather than the historically transactional relationships. Read more in this e-book.
Article |
By David Lyon, Ph.D., and John Baumann,Lonza
By transitioning to alternative solvents or leveraging process aids, the challenges associated with the use of these chemicals can be addressed, helping create a sustainable, greener footprint.
Cryo electron microscopy can help you determine structures for challenging proteins such as membrane proteins and larger complexes. This presentation offers tips on purifying your cryo-EM samples.
To ensure that a commercial biomanufacturing process is in a state of control, life sciences companies must create and successfully execute initiatives to meet continued process verification (CPV) and other monitoring guidelines. Learn how to navigate the major steps of implementing a global monitoring plan for continued process verification.
A model of human IBD has been established to enable the screening and detailed characterization of novel therapeutic agents combining measures that bridge noninvasive and high-throughput testing with clinically relevant endpoints of this disease.
A pharmaceutical company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites, and exemplary quality systems/US FDA track records.
Gain insights into a “simul-spray” process pioneered for combining small and large molecules into a single, atomized drug product for inhalation administration.
Review key approaches and technologies that enable a DNA to IND timeline, with case study examples for application in vector, process, analytic, and formulation development.
